Reference priceRUB ₽484.00Original source price: INR 440.00. Converted estimates are available by currency selection.
| Brand | Ebglyss |
|---|---|
| Manufacturer | Almirall AG |
| Prescription required | Yes |
Ebglyss 250mg/2mlFertigspritze,2 x 2ml(lebrikizumab)
lebrikizumab
Description
Ebglyss 250mg/2mlFertigspritze,2 x 2ml(lebrikizumab) is a medicine catalog record in the MediPriceHub database. Active ingredient: lebrikizumab. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Almirall AG. Therapeutic category: Medicine Library > Dermatology Medicines > Skin inflammation. Pack information: 250 / 2, 1 x 2, 2 x 1. Origin country or market: Switzerland. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
EBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids.How to Use
Use lebrikizumab under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: lebrikizumab. Pack size: 250 / 2, 1 x 2, 2 x 1. Pack unit: box. Manufacturer: Almirall AG. Origin country: Switzerland. Source category: Medicine Library > Dermatology Medicines > Skin inflammation. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Possible adverse effects vary by active ingredient, dose, route, treatment duration, and patient condition. Common issues may include gastrointestinal symptoms, headache, dizziness, fatigue, rash, allergic reactions, or abnormal laboratory tests. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Эта информация носит справочный характер. Перед применением лекарства проконсультируйтесь с медицинским специалистом.